Related Experiment Video

Updated: Mar 15, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

12.3K

Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and

Lucy M De La Cruz1, Nadia F Nocera1, Brian J Czerniecki2

  • 1Department of Endocrine & Oncologic Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

Immunotherapy
|September 9, 2016
PubMed

Insights

Restoring the anti-HER2 CD4(pos) Th1 immune response with dendritic cell vaccines (DC1) can impact HER2+ breast cancer progression. This approach may improve outcomes and eliminate treatment-resistant cancer cells.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • HER2/neu protein is present in most in situ breast cancers and 20-30% of invasive breast cancers (IBC).
  • A decline in anti-HER2 CD4(pos) Th1 (anti-HER2Th1) immune response occurs during breast cancer progression, from benign to IBC stages.
  • The anti-HER2Th1 response is a predictor of neoadjuvant therapy response, recurrence risk, and disease-free survival.

Purpose of the Study:

  • To review the role of anti-HER2Th1 response in breast cancer immunoediting.
  • To explore the potential of dendritic cell vaccines (DC1) in reversing immune evasion in HER2+ breast cancer.

Main Methods:

  • Review of existing literature on HER2/neu expression, anti-HER2Th1 response, and DC1 vaccines in breast cancer.
  • Discussion of the three phases of immunoediting (elimination, equilibrium, escape) in HER2+ breast cancer development.

Main Results:

  • Anti-HER2Th1 response is progressively lost during breast cancer development, correlating with disease progression.
  • HER2-pulsed type I polarized dendritic cells (DC1) can restore the anti-HER2Th1 response.
  • DC1 vaccines show potential clinical impact when administered during ductal carcinoma in situ and early IBC.

Conclusions:

  • Restoring the anti-HER2Th1 immune response via DC1 vaccines offers a promising strategy for improving outcomes in HER2+ breast cancer.
  • DC1 vaccines, alone or combined with standard therapies, may help eliminate treatment-resistant HER2+ breast cancer variants.
Keywords:
adoptive cell therapycheckpoint inhibitorchemotherapydendritic cellimmunotherapymultimodalityradiotherapytargeted therapy

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.8K
Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo10:35

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

4.1K

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K